Needham Maintains Buy on Verrica Pharmaceuticals, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Verrica Pharmaceuticals (NASDAQ:VRCA) but lowers the price target from $16 to $12.
August 15, 2024 | 9:29 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Verrica Pharmaceuticals but lowers the price target from $16 to $12.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations for short-term performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100